EN DE
Watch ACADIA Pharmaceuticals Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

ACADIA Pharmaceuticals Inc (ACAD) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of ACADIA Pharmaceuticals Inc stock $19.54, price $21.23, that is 8.0% below the price, quality 67 out of 100. Rating: fairly valued. Calculated from audited financials with 24 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US

AP ACADIA Pharmaceuticals Inc logo Some data Nov 8, 2026

ACADIA Pharmaceuticals Inc

ACAD · US
Fairly valued, in a downtrend

The stock costs about what our calculation considers fair.

Quality 67/100
Solidly profitable · 33.4% net margin (TTM) · excl. one-off gain FY2025 13.1%
Low debt
Generates free cash flow
Ranks above peers (10/14)
Positive coverage
Revenue last quarter +16% vs. a year ago.
Fair value $19.54 · Fairly valued (−8.0%)
Mixed Growth (revenue 5y +19.4 %/yr in USD)
Wide moat 78/100 · thin data
Insiders sold $1.5M (6M)
Some data
Watch ACADIA Pharmaceuticals Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$33.47 $13.01 Fair Value $19.54 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 8, 2026.

How to read this chart

60‑month range $13.01 – $33.47 · fair‑value band $10.72 – $33.77 · the $21.23 price screens above the $19.54 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 8, 2026.

Follow ACADIA Pharmaceuticals in your weekly email

Every Wednesday you see whether ACADIA Pharmaceuticals is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America.

Show moreShow less

The company offers NUPLAZID (pimavanserin), a selective serotonin inverse agonist/antagonist for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 to treat the symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function.

It also develops remlifanserin, which is in phase 2 clinical trial for the treatment of alzheimer's disease psychosis and lewy body dementia psychosis; ACP-211, which is in phase 2 clinical trial to treat major depressive disorder; ACP-711, which is in phase I clinical trial for the treatment of essential tremor; and ACP-271, a GPR88 agonist for the treatment of tardive dyskinesia and huntington's disease and is in phase I trial.

In addition, the company develops ACP-2591, a cGP analogue which is in Phase 1 clinical trial to treat rett syndrome and fragile X syndrome; and STOKE Antisense Oligonucleotide Program, which is in discovery program for SYNGAP1 syndrome.

It has a license agreement with Neuren Pharmaceuticals Limited to trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop, and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997.

ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

Stock analysis

ACADIA Pharmaceuticals Inc (ACAD) currently trades at $21.23, while our model-based Fair Value estimate is $19.54, so the stock looks roughly fairly valued today (gap 8.6%).

Show more

Valuation

Bull case: the Growth Earnings group reads highest at a median of $105.43 per share, and 11 of the 24 models we run sit above the $21.23 price.

Bear case: the Asset-Based group reads lowest at $4.21, and 13 of the 24 models stay below the price. Data coverage for this calculation is medium.

Scenario range: $10.72 (bear) to $33.77 (bull), the price of $21.23 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 67/100 (solid quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

ACADIA Pharmaceuticals Inc reported revenue of $1.1B in FY2025 versus $484M in FY2021, a compound +22.0%/yr. Reported net income was $391M in FY2025.

Key figures

Market cap $3.7B Mid · P/E ratio 9.5 · P/S ratio 3.22 · EPS (TTM) $2.23 · Net margin 33.4% · Return on equity 35.7% · Return on assets (EBIT) −9.2% (5-year average) · Operating margin 12.3%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 78 out of 100 (low confidence).

What moves the price

Analysts expect earnings well below the last reported figure (earnings in transition, for example expiring patents or contracts); a fair value that looks fair on trailing earnings may then be too optimistic.

The share trades about 31% below its 52-week high and 14% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −8%, ACAD screens richer than that median.

Fair Value models

Bear $10.72 Fair Value $19.54 Bull $33.77
Price $21.23 · Downside -8.0%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then ($1.91 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF $11.34 $16.94 $34.43 74
EPV $6.03 $6.82 $7.51 74
Growth DCF $10.72 $19.54 $33.77 73
All 24 models by family
DCF Models
FCF DCF $11.34 $16.94 $34.43 74
Owner Earnings $28.26 $61.53 $129.04 68
5Y Revenue Exit $8.36 $13.36 $23.81 68
5Y EBITDA Exit $9.22 $15.11 $26.65 70
5Y P/E Exit $31.68 $76.23 $138.09 65
10Y Revenue Exit $9.12 $17.95 $23.30 64
10Y EBITDA Exit $9.99 $19.78 $36.48 63
10Y P/E Exit $26.04 $67.13 $137.26 57
Earnings-Based
Graham-Dodd $15.43 $107.61 $151.02 61
Lynch FV $55.60 $79.42 $103.25 59
PEG = 1.0 $55.60 $79.42 $103.25 55
EPV $6.03 $6.82 $7.51 74
Multiples
P/E Multiple $37.44 $49.92 $62.40 63
P/S Multiple $16.32 $21.77 $27.21 58
P/B Multiple $21.91 $29.21 $36.51 55
EV/EBIT $8.48 $11.07 $13.65 66
EV/EBITDA $7.83 $10.20 $12.57 67
EV/Revenue $6.26 $8.64 $11.01 54
Asset-Based
NCAV (Graham) $2.78 $4.21 $5.26 55
Growth DCF
Growth DCF $10.72 $19.54 $33.77 73
Rev-Margin DCF $9.10 $15.14 $27.81 67
Economic Profit
Residual Income $14.44 $22.05 $53.10 61
ROIC Compounder $6.03 $6.82 $8.17 70
Growth Earnings
Growth-Adj P/E $73.80 $105.43 $137.06 65

Open the full fair value analysis →

Quality Score breakdown

Overall quality 67/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 89
How much profit the company makes from its sales and capital
Quality Growth 57
Are margins and returns getting better?
Cashflow 48
Do the profits arrive as real cash?
Financial strength 88
Debt, balance sheet and risk of trouble
Investment 33
Does it invest with discipline instead of growing at any price?
Low Volatility 59
How calm the share price moves, does not count
Price momentum 22
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 25
Distance to the 52-week high, does not count
New shares 68
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, 3 officers or directors sold shares worth $1.5M and none bought.

  • SaleMark C. SchneyerEVP, CHIEF FINANCIAL OFFICER6× since Nov 18, 2025: 47,324 shares, avg. $25.26$1.2MOct 30, 202610b5-1 plan
  • SaleElizabeth H.Z. ThompsonEVP, Head of Research & Dev2× since Mar 25, 2026: 19,993 shares, avg. $25.33$506,412Jul 30, 202610b5-1 plan
  • SaleJames KiharaPRINCIPAL ACCOUNTING OFFICER6× since Nov 18, 2025: 25,210 shares, avg. $23.91$602,788Jun 26, 2026
  • SaleJennifer J RhodesEVP, CHIEF LEGAL OFFICER, SEC2× since Feb 9, 2026: 10,794 shares, avg. $22.70$245,022Mar 25, 202610b5-1 plan
  • SaleAdams Catherine OwenChief Executive Officer, Director11,641 shares at $21.47$249,932Mar 25, 202610b5-1 plan
  • SaleJames M DalyDirector30,000 shares at $22.37$671,100Nov 10, 2025

Plus 10 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 6, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 77/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+11.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+27.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+19.4%
Start year 2020 (pandemic). Over 10 years: +165.7% a year
Revenue growth 25 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+24.7%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−64.9% (2020) → 9.8% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: no profitable base year
not computed

Growth Forecast

Price in line with expectations
The price assumes less growth than the company has delivered so far and about what analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+14.5%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+12.1%
Yearly sales growth analysts expect, extended to five years.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +11.8% a year for the price and +9.5% for the forecasts.
Forecast 2026 (sales)+18.7%
Forecast 2027 (sales)+12.4%
Projected 2028 (sales)+11.1%
Projected 2029 (sales)+9.8%
Projected 2030 (sales)+8.5%

Watch ACAD, get fair value alerts →

Earlier news

News mood ⓘNews mood, the average tone of recent news (98 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation. Positive
Recent news coverage is more positive than average.
Note from the team Oct 11, 2026
AI conclusion: The likely settlement extends exclusivity for the core Nuplazid franchise into the late 2030s, providing a key strength, while thin evidence for a durable moat remains the main weakness.
Main risk: Eventual generic pressure once the extended protection ends would hit the main revenue driver Nuplazid directly.
Acadia and Zydus filed to dismiss their Nuplazid patent litigation just weeks before trial, signaling a likely settlement that could extend exclusivity into the late 2030s. This de-risks the main revenue driver even as the firm advances remlifanserin to phase three after a narrow miss. Does the added runway for the core franchise outweigh the eventual generic pressure once that protection ends?
Join the discussion →

Compare ACADIA Pharmaceuticals Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 558 stocks

Beats the industry median on 9/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 67 · Top 25%
Fair Value upside −8.0% · Above median
Profitability
Return on equity (12 months) 35.7% · Top 25%
Return on assets 25.0% · Top 25%
Net margin (12 months) 33.4% · Top 25%
Operating margin (12 months) 12.3% · Above median
Growth and dividend
Revenue growth (quarter YoY) 16.4% · Above median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/E (12 months) 9.5× · Cheapest 25%
P/B 2.99× · Pricier than median
P/S (12 months) 3.22× · Cheaper than median
Price / free cash flow (fiscal year) 34.9× · Pricier than median
EV/EBITDA 35.5× · Priciest 25%
PEG 50.86× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)23 · sector 0
FUTURE (revenue growth)82 · sector 0
PAST (return on equity)100 · sector 0
HEALTH (low debt)100 · sector 97
DIVIDEND (yield)0 · sector 22

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Incyte Corporation INCY $119.65 $199.23 +67% vs ACAD
Regeneron Pharmaceuticals, Inc REGN $904.35 $1,275 +41% vs ACAD
Genmab A/S GMAB kr 3,527 kr 3,999 +13% vs ACAD
Samsung Biologics Co 207940 1,516,000 KRW 1,667,600 KRW +10% vs ACAD
WuXi Biologics (Cayman) Inc 2269 HK$47.62 HK$52.38 +10% vs ACAD
Vertex Pharmaceuticals Incorporated VRTX $547.09 $596.75 +9% vs ACAD
argenx SE ARGX $927.21 $908.40 −2% vs ACAD
CSL Limited CSL A$202.04 A$183.04 −9% vs ACAD
Celltrion, Inc 068270 211,000 KRW 74,945 KRW −64% vs ACAD
Royalty Pharma plc RPRX $67.30 $19.01 −72% vs ACAD

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Evidence & backtest34 years, failed companies included Financial calculatorsDCF, Graham, PEG and more
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

ACADIA Pharmaceuticals Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "ACADIA Pharmaceuticals Inc Fair Value". https://www.fairvalue-calculator.com/stock/ACAD

Frequently asked questions

Is ACADIA Pharmaceuticals Inc (ACAD) overvalued or undervalued?
As of Nov 8, 2026, our model estimates a fair value of $19.54 versus a price of $21.23, about 8% lower (fairly valued).
What is the fair value of ACAD?
Our model-based fair value for ACADIA Pharmaceuticals Inc is $19.54 (as of Nov 8, 2026), built from audited fundamentals. The current price: $21.23.
What is the quality score of ACAD?
ACADIA Pharmaceuticals Inc has a Quality Score of 67/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for ACADIA Pharmaceuticals Inc (ACAD)?
Our model-based price target is the fair value of $19.54 (as of Nov 8, 2026) from 24 valuation models. Cautious scenario $10.72, optimistic scenario $33.77. It is a calculation from audited fundamentals, not an analyst target.
What is the ACADIA Pharmaceuticals Inc stock forecast for 2026?
Our models put fair value at $19.54, about 8% lower versus a price of $21.23 (fairly valued). Cautious scenario $10.72, optimistic scenario $33.77. The calculation is refreshed regularly with new filings.
What is the revenue of ACADIA Pharmaceuticals Inc (ACAD)?
ACADIA Pharmaceuticals Inc reported trailing-twelve-month revenue of about $1.1B (latest available figure, as of Nov 8, 2026).
What growth is priced into ACADIA Pharmaceuticals Inc (ACAD)?
For today's price to be fair in a discounted-cash-flow model, ACADIA Pharmaceuticals Inc would have to grow free cash flow by +14.5 % per year for five years (discount rate 9.5 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +19.4 % per year. As of Nov 8, 2026.
What discount rate (WACC) does the fair value of ACAD use?
Our models discount ACADIA Pharmaceuticals Inc at 9.5 %: a base by market capitalisation (mid), damped by beta 0.89, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For ACADIA Pharmaceuticals Inc that is +14.5 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (9.5 %) and the same formula as our fair value.
How much growth has ACADIA Pharmaceuticals Inc (ACAD) delivered so far?
Over the past 5 years revenue at ACADIA Pharmaceuticals Inc grew +19.4 % a year. The price currently implies free-cash-flow growth of +14.5 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of ACADIA Pharmaceuticals Inc (ACAD) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into ACADIA Pharmaceuticals Inc (+14.5 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of ACADIA Pharmaceuticals Inc (ACAD)?
The free-cash-flow yield on the price is 2.87 %: that much free cash flow ACADIA Pharmaceuticals Inc produces per unit of market value. When it exceeds the discount rate of our models (9.5 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of ACADIA Pharmaceuticals Inc (ACAD)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For ACADIA Pharmaceuticals Inc it is $19.54 per share (as of Nov 8, 2026), against a price of $21.23. It is the blended result of 24 valuation models in 7 families (DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is ACADIA Pharmaceuticals Inc stock overvalued or undervalued in 2026?
As of Nov 8, 2026, ACAD trades above its calculated fair value: price $21.23, fair value $19.54, a gap of about −8% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ACAD?
No. The price is what the market pays today ($21.23); the fair value is what the company's own numbers justify ($19.54). For ACADIA Pharmaceuticals Inc the two are $1.69 per share apart. That gap is exactly why we show both numbers side by side.
How much is ACADIA Pharmaceuticals Inc worth?
The market values ACADIA Pharmaceuticals Inc at about $3.7B (market capitalisation, as of Nov 8, 2026). Per share that is $21.23; our models calculate a fair value of $19.54 per share.
What do the bullish and bearish scenarios say about ACAD?
Our models span a range for ACADIA Pharmaceuticals Inc: cautious scenario $10.72, base $19.54, optimistic $33.77 per share (as of Nov 8, 2026, price $21.23). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of ACAD?
ACADIA Pharmaceuticals Inc trades at a price-to-earnings ratio of 9.5 (as of Nov 8, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $19.54 is built from several models across several years. Other multiples: PEG 50.9, P/B 3.0, P/S 3.2, EV/EBITDA 35.5.
What is the PEG ratio of ACAD?
The PEG ratio of ACADIA Pharmaceuticals Inc is 50.86 (P/E divided by earnings growth, as of Nov 8, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of ACADIA Pharmaceuticals Inc (ACAD)?
Balance-sheet figures for ACADIA Pharmaceuticals Inc (as of Nov 8, 2026): return on equity 35.7%. They feed the Quality Score of 67/100, which measures business quality independently of the share price.
How far is ACAD from its 52-week high?
ACADIA Pharmaceuticals Inc trades at $21.23, about 31% below its 52-week high of $30.57 and 14% above the low of $18.62 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of $19.54 is for.
Which stocks are comparable to ACADIA Pharmaceuticals Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is ACADIA Pharmaceuticals Inc stock attractive at the current price?
The data as of Nov 8, 2026: price $21.23, calculated fair value $19.54 (−8%), Quality Score 67/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of ACAD calculated?
We run ACADIA Pharmaceuticals Inc through 24 models from 7 families: DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of $19.54 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0% above its aggregate fair value. ACADIA Pharmaceuticals Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of ACADIA Pharmaceuticals Inc (ACAD)?
The closing price on Nov 6, 2026 was $21.23. Our model-based fair value is $19.54, about 8% lower (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with ACADIA Pharmaceuticals Inc right now?
The model range is unusually wide ($10.72 to $33.77). The outcome hinges heavily on assumptions, so read the point estimate with caution. The price sits close to our fair value, market and models broadly agree here, little valuation tension.

Key figures of ACADIA Pharmaceuticals Inc

How large is the market capitalisation of ACADIA Pharmaceuticals Inc (ACAD)?
The market capitalisation of ACADIA Pharmaceuticals Inc is $3.7B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of ACADIA Pharmaceuticals Inc (ACAD)?
The price-to-sales ratio of ACADIA Pharmaceuticals Inc is 3.22 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of ACADIA Pharmaceuticals Inc (ACAD)?
Earnings per share at ACADIA Pharmaceuticals Inc are $2.23 (price ÷ EPS = P/E 9.5). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of ACADIA Pharmaceuticals Inc (ACAD)?
The net margin of ACADIA Pharmaceuticals Inc is 33.4% (last twelve months), excl. one-off gain FY2025 13.1%. How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of ACADIA Pharmaceuticals Inc (ACAD)?
The return on equity (ROE) of ACADIA Pharmaceuticals Inc is 35.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of ACADIA Pharmaceuticals Inc (ACAD)?
On an EBIT basis the return on assets of ACADIA Pharmaceuticals Inc is −9.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of ACADIA Pharmaceuticals Inc (ACAD)?
The operating margin of ACADIA Pharmaceuticals Inc is 12.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at ACADIA Pharmaceuticals Inc (ACAD)?
Revenue at ACADIA Pharmaceuticals Inc is growing +16.4% versus a year earlier (3y avg +27.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at ACADIA Pharmaceuticals Inc (ACAD)?
Earnings per share at ACADIA Pharmaceuticals Inc are growing +13.3% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does ACADIA Pharmaceuticals Inc (ACAD) hold?
ACADIA Pharmaceuticals Inc holds more cash than debt, $126M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch ACADIA Pharmaceuticals Inc in the live analysis

One click puts ACADIA Pharmaceuticals Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.